-
公开(公告)号：US20230098083A1
公开(公告)日：2023-03-30
申请号：US17983915
申请日：2022-11-09
申请人： MannKind Corporation
发明人： P. Spencer Kinsey , Brendan Laurenzi , Chad C. Smutney , Benoit Adamo , Joseph Guarneri , John J. Freeman, JR.
IPC分类号： A61M15/00 , A61K9/00 , A61K31/352 , A61K31/495 , A61K31/661
摘要： A dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed. The inhalers are used with inhalable dry powders, including medicament formulations comprising active agents for local or systemic delivery and for the treatment of diseases such as, pulmonary hypertension, cardiovascular disease, anaphylaxis, diabetes, obesity, cancer, and other diseases, or symptoms associated with these and other diseases, such as nausea, vomiting, pain and inflammation.
-
公开(公告)号：US20220387593A1
公开(公告)日：2022-12-08
申请号：US17887856
申请日：2022-08-15
申请人： MannKind Corporation
IPC分类号： A61K45/06 , A61K38/26 , A61K38/28 , A61K31/495 , A61M15/00
摘要： A method for preventing or reducing adverse effects such as profuse sweating, nausea and vomiting, which normally are associated with subcutaneous and intravenous administration of glucagon-like peptide 1 (GLP-1) therapy is provided. In particular, the method comprises the rapid administration of a GLP-1 formulation into the pulmonary circulation such as by inhalation, directly into pulmonary alveolar capillaries using a dry powder drug delivery system.
-
公开(公告)号：US20220370444A1
公开(公告)日：2022-11-24
申请号：US17755425
申请日：2020-11-01
申请人： MannKind Corporation
发明人： Thomas Hofmann , Stefan Ufer , Kevin Stapleton
IPC分类号： A61K31/498 , A61K9/00 , A61K9/16 , A61K31/47 , A61K31/606 , A61K31/546 , A61K31/7036 , A61K31/7048 , A61K31/4965 , A61K31/496 , A61K31/4709 , A61K31/5383
摘要： The present invention relates to pharmaceutical compositions for inhalation comprising a therapeutically effective dose of clofazimine wherein the clofazimine is provided in the form of dry powder, and processes for their preparation. Furthermore, the present invention provides pharmaceutical combinations comprising clofazimine in the form of an aerosol for pulmonary inhalation. The combinations and compositions provided by the present invention may be used in the treatment and/or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria, and of pulmonary fungal infections.
-
公开(公告)号：US20220362147A1
公开(公告)日：2022-11-17
申请号：US17864828
申请日：2022-07-14
申请人： MannKind Corporation
IPC分类号： A61K9/00 , A61K9/16 , A61K31/495 , A61K38/26
摘要： A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.
-
公开(公告)号：US20220152025A1
公开(公告)日：2022-05-19
申请号：US17528011
申请日：2021-11-16
IPC分类号： A61K31/506 , A61K9/00
摘要： Methods of treatment of pulmonary hypertension comprising dry powder inhalation administration of imatinib, a pharmaceutically acceptable salt, or a derivative thereof, are provided. Dry powder inhalable compositions comprising imatinib, a pharmaceutically acceptable salt, or a derivative thereof, are also provided as well as methods of making the same.
-
公开(公告)号：US11304992B2
公开(公告)日：2022-04-19
申请号：US16721357
申请日：2019-12-19
申请人： MannKind Corporation
IPC分类号： A61K31/706 , A61K9/00 , A61K38/26 , A61K45/06 , A61K31/4965 , A61K47/26
摘要： A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
-
公开(公告)号：US11292774B2
公开(公告)日：2022-04-05
申请号：US16798690
申请日：2020-02-24
申请人： MannKind Corporation
IPC分类号： C07D241/08 , B01J27/16
摘要： Provided is a method for the synthesis of N-protected 3,6-bis-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ε-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide.
-
公开(公告)号：US20210244897A1
公开(公告)日：2021-08-12
申请号：US17244730
申请日：2021-04-29
申请人： MannKind Corporation
发明人： Chad C. Smutney , Benoit Adamo , John M. Polidoro , P. Spencer Kinsey , Dennis Overfield , Carl R. Sahi , Christine Billings , Mark T. Marino
摘要： A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity.
-
公开(公告)号：US11013788B2
公开(公告)日：2021-05-25
申请号：US16385915
申请日：2019-04-16
申请人： MannKind Corporation
IPC分类号： A61K38/28 , A61K31/155 , A61K9/00
摘要： Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
-
公开(公告)号：US20210146071A1
公开(公告)日：2021-05-20
申请号：US17158997
申请日：2021-01-26
申请人： MannKind Corporation
发明人： P. Spencer Kinsey , Brendan Laurenzi , Chad C. Smutney , Benoit Adamo , Joseph Guarneri , John J. Freeman, JR.
IPC分类号： A61M15/00 , A61K9/00 , A61K31/352 , A61K31/495 , A61K31/661
摘要： A dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed. The inhalers are used with inhalable dry powders, including medicament formulations comprising active agents for local or systemic delivery and for the treatment of diseases such as, pulmonary hypertension, cardiovascular disease, anaphylaxis, diabetes, obesity, cancer, and other diseases, or symptoms associated with these and other diseases, such as nausea, vomiting, pain and inflammation.
-
-
-
-
-
-
-
-
-
搜索结果
369 条记录 (耗时 0.029 秒)
